NDAINJECTIONINJECTABLE
Approved
Jun 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Clinical Trials (5)
A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP
Started Jan 2026
420 enrolled
Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Assess the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Meropenem-Pralubactam (Meropenem/FL058) in China Healthy Adult Participants
Started Sep 2025
16 enrolled
Infections
Evaluation of the Concentration of ANT3310 and Meropenem in the Lung in Healthy Adult Participants
Started Apr 2025
26 enrolled
Pharmacokinetics Study on Healthy Volunteers Adults
Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections
Started Apr 2025
80 enrolled
Hospital-acquired Bacterial Pneumonia (HABP)Ventilator-associated Bacterial Pneumonia (VABP)Complicated Intra-abdominal Infection (cIAI)+2 more
Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens
Started Mar 2025
176 enrolled
Febrile Neutropenia